- Home
- BANX vs BDTX Comparison
BANX vs BDTX Comparison
Compare BANX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANX | BDTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.0M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BANX | BDTX |
|---|---|---|
| Price | $21.00 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 23.4K | ★ 920.8K |
| Earning Date | 06-17-2025 | 03-05-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | 0.38 |
| Revenue | $29,467,794.00 | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.88 | ★ $6.67 |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $17.99 | $1.20 |
| 52 Week High | $21.67 | $4.94 |
Technical Indicators
Market Signals| Indicator | BANX | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 37.24 |
| Support Level | $20.80 | $2.49 |
| Resistance Level | $21.56 | $2.64 |
| Average True Range (ATR) | 0.48 | 0.15 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 32.64 | 12.24 |
Price Performance
Historical ComparisonAbout BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.